SCHEMBL4117410

SCHEMBL4117410

Cc1cc2c(cc1C)C(OC(=O)N1CCN(C)CC1)N(c1cccc(F)c1)C2=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 1/20 0.41
KMT2A Q03164 1/20 0.40
TP53 P04637 1/20 0.40
LMNA P02545 2/20 0.39
ATM Q13315 1/20 0.38
MAPT P10636 2/20 0.37
TSHR P16473 2/20 0.37
ALDH1A1 P00352 1/20 0.37
HPGD P15428 1/20 0.37
CASP1 P29466 1/20 0.37
HTT P42858 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
CYP2D6 P10635 2/20 0.36
CYP2C19 P33261 2/20 0.36
MAPK1 P28482 1/20 0.36
ADORA3 P0DMS8 1/20 0.36
RECQL P46063 1/20 0.36
GABRA1 P14867 1/20 0.36
GABRA3 P34903 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4109186 0.85 GAA (0.41) KMT2AATMALDH1A1MMP2ADAMTS5
SCHEMBL3745282 0.84 ATM (0.43) FAAHKMT2ATP53LMNAATM
SCHEMBL4128092 0.81 ADAMTS5 (0.39) KMT2AATMALDH1A1HTTSMN1; SMN2
SCHEMBL4117459 0.76 NOTUM (0.37) LMNAALDH1A1HPGDSMN1; SMN2NPSR1
SCHEMBL4127465 0.74 MEN1 (0.42) FAAHKMT2ATP53ATMTSHR
SCHEMBL4110694 0.74 NOTUM (0.40) FAAHTP53LMNAALDH1A1HPGD
SCHEMBL4115204 0.73 ALDH1A1 (0.45) KMT2ATP53LMNAMAPTALDH1A1
SCHEMBL4128095 0.73 HSD11B1 (0.33) KMT2ATSHRHPGDCYP2D6CYP2C19
SCHEMBL4118353 0.71 NOTUM (0.38) KMT2ALMNAALDH1A1HPGDHTT
SCHEMBL13775392 0.70 ATM (0.40) KMT2AATMHTTSMN1; SMN2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1566378-B1 ISOINDOLINE DERIVATIVE MARUISHI PHARMA (JP) 2012-08-15 EP disclosed
US-20090170835-A1 ISOINDOLINE DERIVATIVES MARUISHI PHARMACEUTICAL CO., LTD. 2009-07-02 US disclosed
US-7521451-B2 Isoindoline derivative MARUISHI PHARMACEUTICAL CO., LTD. (JP) 2009-04-21 US disclosed
US-20060052392-A1 e.g. 5,6-dimethyl-3a,4,7,7a-tetrahydro-2-benzofuran-1,3-dione;intravenous, water-soluble compounds useful for manufacturing an anasthetic, sedative agents; side effect reduction MARUISHI PHARMACEUTICAL CO., LTD 2006-03-09 US disclosed
EP-1566378-A1 ISOINDOLINE DERIVATIVE Maruishi Pharmaceutical Co., Ltd. (JP) 2005-08-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060052392-A1 e.g. 5,6-dimethyl-3a,4,7,7a-tetrahydro-2-benzofuran-1,3-dione;intravenous, water-soluble compounds useful for manufacturing an anasthetic, sedative agents; side effect reduction CYP3A5, OPRD1, CYP3A7 FAAH 194/4885KMT2A 1256/4885TP53 3654/4885
US-20090170835-A1 ISOINDOLINE DERIVATIVES OPRD1, OPRK1, OPRL1 FAAH 432/4885KMT2A 1230/4885TP53 4669/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.